Use of recombinant viruses to assess the pattern of early human immunodeficiency virus breakthrough infection in the presence of stavudine

Journal of General Virology

Volumn 80, Issue 9, 1999, Pages 2361-2367

  Medina, Daniel J ^a   Tung, Peter P ^b   Strair, Roger K ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; FLOXURIDINE; STAVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; CELL LINE; HOST CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MONONUCLEAR CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RETROVIRUS; VIRUS RECOMBINANT; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS; MURINAE; RNA VIRUSES; UNIDENTIFIED RETROVIRUS;

EID: 0032859817     PISSN: 00221317     EISSN: None     Source Type: Journal    
DOI: 10.1099/0022-1317-80-9-2361     Document Type: Article

References (22)

1. Ahluwalia, G. S., Gao, W. Y., Mitsuya, H. & Johns, D. G. (1996). 2′,3′-Didehydro-3′-deoxythymidine: regulation of its metabolic activation by modulators of thymidine-5′-triphosphate biosynthesis. Molecular Pharmacology 50, 160-165.
2. Finzi, D. & Siciliano, R. F. (1998). Viral dynamics in HIV-1 infection. Cell 93, 665-671.
3. Gulick, R. M., Mellors, J. W., Havlir, D., Eron, J. J., Gonzalez, C., McMahon, D., Richman, D. D., Valentin, F. T., Jonas, L. & Meibohm, A. (1997). Treatment with indinavir, zidovudine and lamivudine in adults with human immunodeficiency infection and prior antiretroviral therapy. New England Journal of Medicine 337, 734-739.
4. Havlir, D. & Richman, D. D. (1994). Viral dynamics of HIV: implications for drug development and therapeutic strategies. Annals of Internal Medicine 124, 984-989.
5. Havlir, D. V., Gamst, A., Eastman, S. & Richman, D. D. (1996). Nevirapine-resistant human immunodeficiency virus: kinetics of replication and estimated prevalence in untreated patients. Journal of Virology 70, 7894-7899.
6. Lacey, S. F. & Larder, B. A. (1994). Novel mutation (V75T) in human immunodeficiency virus type I reverse transcriptase confers resistance to 2′,3′-didehydro-2′,3′-dideoxythymidine in cell culture. Antimicrobial Agents & Chemotherapy 38, 1428-1432.
7. Lin, P. F., Samanta, H., Rose, R. E., Patick, A. K., Trimble, J., Bechtold, C. M., Revie, D. R., Khan, N. C., Federici, M. E., Li, H. & Colonno, R. J. (1994). Genotypic and phenotypic analysis of human immunodeficiency virus type I isolates from patients on prolonged stavudine therapy. Journal of Infectious Diseases 170, 1157-1164.
8. Loveday, C., Kaye, S., Tenant-Flowers, M., Semple, M., Ayliffe, U., Weller, I. D. & Tedder, R. S. (1995). HIV-1 RNA serum load and resistant viral genotypes during early zidovudine therapy. Lancet 345, 820-825.
9. Medina, D. J., Tung, P. P., Lemer-Tung, M. B., Nelson, C. J., Mellors, J. W. & Strair, R. K. (1995). Sanctuary growth of human immunodeficiency virus in the presence of 3′-azido-3′-deoxythymidine (AZT). Journal of Virology 69, 1606-1611.
10. Medina, D. J., Tung, P. P., Sathya, B. & Strair, R. K. (1996). Use of floxuridine to modulate the antiviral activity of zidovudine. AIDS Research and Human Retroviruses 12, 965-968.
11. Medina, D. J., Tung, P. P., Nelson, C. J., Sathya, B., Casareale, D. & Strair, R. K. (1998). Characterization and use of a recombinant retroviral system for the analysis of drug resistant HIV. Journal of Virological Methods 71, 169-176.
12. Miller, A. D. & Rosman, G. T. (1989). Improved retroviral vectors for gene transfer and expression. Biotechniques 7, 980-990.
13. Mosman, T. (1983). Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. Journal of Immunological Methods 65, 55-63.
14. Najera, I., Holquin, A., Quinones-Mateu, M. E., Munoz-Fernandez, M. A., Najera, R., Lopez-Galindez, C. & Domingo, E. (1995). Pol gene quasispecies of human immunodeficiency virus: mutations associated with drug resistance in virus from patients undergoing no drug therapy. Journal of Virology 69, 23-31.
15. Page, K. A., Landau, N. & Littman, D. R. (1990). Construction and use of a human immunodeficiency virus vector for analysis of viral infectivity. Journal of Virology 64, 5270-5276.
16. Perelson, A. S., Neumann, A. U., Markowitz, M., Leonard, J. M. & Ho, D. D. (1996). HIV-1 dynamics in vivo: virion clearance rate, infected cell life span, viral generation time. Science 271, 1582-1586.
17. Reed, L. J. & Muench, H. (1938). A simple method for estimating fifty percent end points. American Journal of Hygiene 27, 493-496.
18. Strair, R. K., Nelson, C. J. & Mellors, J. W. (1991). Use of recombinant retroviruses to characterize the activity of antiretroviral compounds. Journal of Virology 65, 6339-6342.
19. Strair, R. K., Medina, D. J., Nelson, C. J., Graubert, T. & Mellors, J. W. (1993). Recombinant retroviral systems for the analysis of drug-resistant HIV. Nucleic Acids Research 21, 4836-4842.
20. Wei, X., Ghosh, S. K., Taylor, M. V., Johnson, V. A., Emini, E. A., Deutch, P., Lifson, J. D., Bonhoeffer, M., Nowak, A., Hahn, B. H., Saag, M. S. & Shaw, G. M. (1995). Viral dynamics in HIV-1 infection. Nature 373, 117-122.
21. Willey, R. L., Smith, D. H., Lasky, L. A., Theodore, T. S., Earl, P. L., Moss, P., Caponi, D. J. & Martin, M. A. (1988). In vitro mutagenesis identifies a region within the envelope gene of the human immunodeficiency virus that is critical for infectivity. Journal of Virology 62, 139-147.
22. Zhang, H., Bagasra, O., Nikura, M., Poiesz, B. J. & Pomerantz, R. J. (1994). Intravirion reverse transcripts in the peripheral blood plasma of human immunodeficiency virus type-1 infected individuals. Journal of Virology 68, 7591-7597.